Latest ADH-1 Stories
A lack of the protein endoglin in the blood vessels of tumor-bearing mice enables the spread of daughter tumors.
Combining two strategies designed to improve the results of cancer treatment – antiangiogenesis drugs and nanomedicines – may only be successful if the smallest nanomedicines are used.
Researchers from UCLA's Jonsson Comprehensive Cancer Center, together with scientists from 12 other sites in the United States and Australia, report for the first time that a newly approved drug for patients with metastatic melanoma nearly doubles median survival times, a finding that will change the way this deadly form of skin cancer is treated.
When cancers become aggressive and spread they are the most deadly.
A new study found that a group of little-explored cells in the tumor microenvironment can likely serve as gatekeepers against cancer progression and metastasis.
Cell-surface protein N-cadherin represents a promising therapeutic target for the treatment of pancreatic cancer.
Massachusetts General Hospital (MGH) researchers have discovered the first of an entirely new class of antiangiogenesis drugs â€“ agents that interfere with the development of blood vessels.
Researchers at the University of Michigan Comprehensive Cancer Center have developed a new drug called AT-406 with potential to treat multiple types of cancer.
A remarkable discovery into how tumor cells invade normal tissue should lead to vital diagnostic tools and help develop strategies to stop the spread of cancer cells.
Researchers have identified a drug combination that shows promise in attacking deadly melanoma.
- A hairdresser.